Centocor, Inc. and Schering-Plough Corp. have been granted approval from the European Commission for Remicade for the treatment of moderate to severe, active ulcerative colitis (UC) in patients who have had an inadequate response to conventional therapy or who are intolerant to such therapies. The approval makes Remicade the first biologic therapy approved to treat active UC in the EU and also marks the eighth indication Remicade has received in the EU for the treatment of immune-mediated inflam...